FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.
What happened
FDA inspected Dr. Jaffrani's clinical site in Alexandria, Louisiana, between February 24 and March 13, 2025, as part of its Bioresearch Monitoring Program, which checks how research is run and whether human subjects are protected. The agency found that for two investigational drug protocols he learned of serious adverse events (SAEs — serious medical events in study subjects) but reported them to the sponsor's safety team days to months later, instead of within the 24 hours the study plans required. FDA reviewed his March 31, 2025 response to the Form FDA 483 (the list of inspection findings given at the end of an inspection) and called it inadequate.
What FDA found
He learned of a subject's heart attack (NSTEMI) on September 2, 2022 but did not report it to the sponsor until September 26, 2022.
21 CFR 312.60He learned on January 5, 2023 of COVID-19 pneumonia, a COPD flare-up and a hospitalization for heart failure, but reported them only on February 21, April 3 and May 1, 2023.
21 CFR 312.60He learned of a pulmonary embolism and deep vein thrombosis on January 13, 2023 but did not report them until May 1, 2023.
21 CFR 312.60He learned of worsening ischemic cardiomyopathy on November 13, 2024 but did not report it until November 24, 2024.
21 CFR 312.60He learned of a post-operative neck hematoma on September 11, 2023 but did not report it until September 15, 2023.
21 CFR 312.60He learned of a subject's hospitalization for low blood pressure on January 30, 2025 but did not report it until February 7, 2025, and he left protocol duties to study coordinators without sufficient oversight.
21 CFR 312.60
What FDA wants
FDA tells him to write back within 15 business days describing the actions he has taken to prevent similar violations, with enough detail to show how he will supervise study staff and how his serious adverse event reporting system will work.
Who should pay attention
- sponsors and contract research organizations running trials at this site
- other clinical investigators who delegate study tasks to coordinators
- IRBs and research sites that oversee investigator conduct
This is a summary. Read the original letter on fda.gov.